This report aims to answer the following questions:
- What does the existing evidence say about the efficacy and safety of novel antipsychotics for treating children and adolescents with attention-deficit hyperactivity disorder (ADHD)?
- What are the financial implications, in terms of additional drug acquisition costs, for the Canadian health care system if novel antipsychotics were to be adopted for this indication?